Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory <i>Mycobacterium avium</i> complex lung disease.

Marras, Theodore K; Hassan, Mariam; Mange, Kevin C; Ciesielska, Monika; Murthy, Shilpa Dhar; Jumadilova, Zhanna; Chatterjee, Anjan

Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease.

Marras, Theodore K; Hassan, Mariam; Mange, Kevin C; Ciesielska, Monika; Murthy, Shilpa Dhar; Jumadilova, Zhanna; Chatterjee, Anjan.

Afiliación

Marras TK; Dept of Medicine, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada.
Hassan M; Insmed Incorporated, Bridgewater, NJ, USA.
Mange KC; Insmed Incorporated, Bridgewater, NJ, USA.
Ciesielska M; Insmed Incorporated, Bridgewater, NJ, USA.
Murthy SD; Insmed Incorporated, Bridgewater, NJ, USA.
Jumadilova Z; Insmed Incorporated, Bridgewater, NJ, USA.
Chatterjee A; Insmed Incorporated, Bridgewater, NJ, USA.

ERJ Open Res ; 8(3)2022 Jul.

Article en En | MEDLINE | ID: mdl-35821755

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: ERJ Open Res Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google